- Report
- April 2025
- 175 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- April 2025
- 175 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- March 2025
- 200 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Drug Pipelines
- April 2025
- 250 Pages
Global
From €2627EUR$3,000USD£2,280GBP
- Report
- March 2025
- 185 Pages
Global
From €3941EUR$4,500USD£3,421GBP
- Clinical Trials
- April 2025
- 80 Pages
Global
From €1752EUR$2,000USD£1,520GBP
- Report
- October 2025
- 137 Pages
Global
From €3502EUR$3,999USD£3,040GBP
- Report
- June 2025
- 146 Pages
Global
From €3502EUR$3,999USD£3,040GBP
- Report
- June 2025
- 150 Pages
Global
From €2364EUR$2,699USD£2,052GBP
- Report
- June 2025
- 150 Pages
Global
From €2364EUR$2,699USD£2,052GBP
- Report
- January 2026
- 149 Pages
Global
From €3459EUR$3,950USD£3,003GBP
- Report
- September 2025
- 113 Pages
Global
From €3500EUR$4,281USD£3,144GBP
- Report
- February 2025
Japan, United States, ... Japan, United States, Europe, Global
From €3284EUR$3,750USD£2,851GBP
- Report
- February 2025
Middle East
From €3941EUR$4,500USD£3,421GBP
- Report
- February 2025
North America, Mexico, ... North America, Mexico, Canada
From €2146EUR$2,450USD£1,862GBP
- Report
- February 2025
Europe, United Kingdom, ... Europe, United Kingdom, Spain, Italy, Germany, France
From €2496EUR$2,850USD£2,166GBP
- Report
- February 2025
United States
From €1270EUR$1,450USD£1,102GBP
- Report
- March 2024
- 102 Pages
Global
From €1489EUR$1,700USD£1,292GBP
- Report
- May 2024
- 137 Pages
Global
From €3502EUR$3,999USD£3,040GBP
- Report
- August 2022
Global
From €3941EUR$4,500USD£3,421GBP

Factor IX is a protein used to treat hemophilia B, a rare genetic disorder that impairs the body's ability to form blood clots. It is a recombinant form of the human factor IX protein, which is produced in a laboratory setting. Factor IX is administered intravenously or subcutaneously to replace the missing clotting factor in patients with hemophilia B. It is used to prevent and treat bleeding episodes, as well as to prevent bleeding during surgery.
Factor IX is a part of the larger hematological drugs market, which includes drugs used to treat blood-related diseases and disorders. These drugs are used to treat a wide range of conditions, including anemia, leukemia, and thrombocytopenia.
Some companies in the Factor IX market include Novo Nordisk, Pfizer, Bayer, and Biogen. Show Less Read more